CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
CTS Tampa has implemented the Ortho Vitros Anti-SARS-CoV-2 Total test which qualitatively detects an...
In 2016, the Procleix Panther instrument was introduced by Grifols in support of automated NAT ZIKA ...
On January 25, 2021, CTS implements the Ortho VIP viral marker testing platform. Conversion from the...
We sincerely hope to see you at this year’s AABB Annual Meeting in Boston, MA on October 12-16...
The new online Learning Center with new content can still be found under the “Training” folder on ...
The FDA Guidance ZIKV video for the webinar held on 08/15/18 has been posted in the Wh...